Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRKD3 | O94806 | 3/20 | 0.49 |
| ▸ | PRKCG | P05129 | 3/20 | 0.49 |
| ▸ | PRKCB | P05771 | 3/20 | 0.49 |
| ▸ | PRKCA | P17252 | 3/20 | 0.49 |
| ▸ | PRKCH | P24723 | 3/20 | 0.49 |
| ▸ | PRKCI | P41743 | 3/20 | 0.49 |
| ▸ | PRKCE | Q02156 | 3/20 | 0.49 |
| ▸ | PRKCQ | Q04759 | 3/20 | 0.49 |
| ▸ | PRKCZ | Q05513 | 3/20 | 0.49 |
| ▸ | PRKCD | Q05655 | 3/20 | 0.49 |
| ▸ | PRKD1 | Q15139 | 3/20 | 0.49 |
| ▸ | PRKACA | P17612 | 3/20 | 0.49 |
| ▸ | PRKACG | P22612 | 3/20 | 0.49 |
| ▸ | PRKACB | P22694 | 3/20 | 0.49 |
| ▸ | MEN1 | O00255 | 2/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.49 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.49 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.49 |
| ▸ | NFKB1 | P19838 | 2/20 | 0.49 |
| ▸ | TP53 | P04637 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12234403 | 0.80 | PKLR (0.42) | PKLRF2FLT3KCNA5P2RX7 | |
| SCHEMBL17737761 | 0.76 | PRKD3 (0.59) | PRKD3PRKCGPRKCBPRKCAPRKCH | |
| SCHEMBL17737346 | 0.75 | MEN1 (0.60) | PRKD3PRKCGPRKCBPRKCAPRKCH | |
| SCHEMBL17737439 | 0.74 | MEN1 (0.54) | PRKD3PRKCGPRKCBPRKCAPRKCH | |
| SCHEMBL1760052 | 0.74 | — | — | |
| SCHEMBL7435898 | 0.72 | PRKCG (0.65) | PRKD3PRKCGPRKCBPRKCAPRKCH | |
| SCHEMBL7433187 | 0.71 | PRKCA (0.60) | PRKD3PRKCGPRKCBPRKCAPRKCH | |
| SCHEMBL7431698 | 0.71 | PRKACA (0.67) | PRKD3PRKCGPRKCBPRKCAPRKCH | |
| SCHEMBL117035 | 0.70 | PRKCG (0.62) | PRKD3PRKCGPRKCBPRKCAPRKCH | |
| SCHEMBL7312125 | 0.70 | PRKACA (0.78) | PRKD3PRKCGPRKCBPRKCAPRKCH |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2011057973-A1 | OXAZOLINE DERIVATIVES FOR TREATMENT OF CNS DISORDERS | F. HOFFMANN-LA ROCHE AG (CH) | 2011-05-19 | — | — | WO | disclosed |
| US-20110112080-A1 | OXAZOLINE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2011-05-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110112080-A1 | OXAZOLINE DERIVATIVES | TAAR1, HCRTR1, NPY1R | PRKD3 3802/4885PRKCG 4348/4885PRKCB 3782/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.